Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ANDA Approval Speed-Up Leaves Sponsors With Less Margin For Error

Executive Summary

Get applications in right, or get a complete response letter, FDA says; firms will have fewer opportunities for mid-review application corrections as review goals reach 10 months.


Related Content

Sentinel May Expand To Generic Equivalence Studies
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs
GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
ANDA Approvals, Submissions Decline With New Review Goal Coming
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst